TB-500

TB-500 is a synthetic fragment of thymosin beta-4 that promotes cell migration, angiogenesis, and tissue repair, run in the community mostly for acute injury and muscle healing. People typically dose around 500 mcg daily, spanning 200 mcg to 10 mg, while clinician protocols land higher at 2 to 2.5 mg daily subcutaneously over 4 to 12 weeks. Injection-site reactions surface occasionally in user reports, but nothing else has been a consistent theme. The honest caveat: there's no FDA-approved indication, all use is off-label, and roughly a third of participants withdrew across the registered trial program.

Half-life~3 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.51.33.63.32.85.0

Research Evidence

Evidence shape

TB-500 currently sits at a moderate evidence tier, though it lacks published human clinical trials to support its use. While ten registered trials have been initiated across eleven distinct indications—ranging from dry eye syndrome to cardiovascular conditions—the research remains exploratory and fragmented, with most indications supported by only a single trial. The quality of this data is limited by a 40% withdrawal rate across the registered studies, and the majority of the clinical pipeline consists of long-tail, single-trial investigations that have yet to establish a consistent therapeutic profile.

Depthhow much
10 registered trials
4 completed · 4 with posted results · 2 recruiting / active · combined n=225
Breadthhow many areas
11 indications mapped
6 thin / exploratory · 1 animal-only · 10 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 2
4 blinded with results · 3 distinct sponsors · 40% withdrawal rate · AE rows aggregated from 3 trials · 1 linked publication on registered trials
Breadth and depth33 rows captured
Human
direct clinical signal
10
Animal
translational support
12
In vitro
mechanistic support
11
HighMediumLow

Anecdotal efficacy

TB-500 side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Bio Supply Uk
GB
5000 mg
$52.35
$0.013/mg
2
Uther
unknown
100 mg×10
$85.00
$0.85/mg
3
High Purity Peptides
Hong Kong
100 mg×10
$130.00
$1.3/mg
4
Nurev Peptides
--
10 mg
$13.99
$1.4/mg
5
Velocity BIO Labs
US
10 mg
$14.99
$1.5/mg
6
Chimera Peptides
CN
100 mg×10
$179.00
$1.79/mg

price offers can be sorted by column · 21 out-of-stock offers not shown

1-6 of 294

TB-500 dosing & protocol

How TB-500 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 4
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
10 mg
no dose captured for this tier yet
Frequency
single dose
Route
IV

No reliable dose information is available for the research‑trial tier of TB‑500; dosing was not reliably extracted across the four completed trials.

4 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Typical dose
2.5 mg2 mg – 2.5 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 7 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Clinician sources most often report 2–2.5 mg of TB‑500 given subcutaneously daily, while one source lists a weekly 2.5 mg dose; no cycling protocol is mentioned.

3 sources
Anecdotal
Community-reported real-world use · n = 35
Typical dose
1 mg100 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 42 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mixed
Route
subQ

Most community reports did not specify a schedule; among those that did, daily dosing (6 reports) was most common, with weekly (4 reports) and less frequent patterns such as twice daily, every other day, or twice weekly each reported once.

35 sources

Related peptides

BPC-157Pentosan PolysulfateARA-290KPVKLOWWolverineB7-33